25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

AAREYDRUGS (Aarey Drugs & Pharmaceuticals Limited) Stock Analysis
Buy, Hold or Sell?

Let's analyze Aarey Drugs & Pharmaceuticals Limited together

I guess you are interested in Aarey Drugs & Pharmaceuticals Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Aarey Drugs & Pharmaceuticals Limited’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Aarey Drugs & Pharmaceuticals Limited’s Price Targets

I'm going to help you getting a better view of Aarey Drugs & Pharmaceuticals Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Aarey Drugs & Pharmaceuticals Limited

I send you an email if I find something interesting about Aarey Drugs & Pharmaceuticals Limited.

1. Quick Overview

1.1. Quick analysis of Aarey Drugs & Pharmaceuticals Limited (30 sec.)










1.2. What can you expect buying and holding a share of Aarey Drugs & Pharmaceuticals Limited? (30 sec.)

How much money do you get?

How much money do you get?
INR0.00
When do you have the money?
1 year
How often do you get paid?
20.0%

What is your share worth?

Current worth
INR48.84
Expected worth in 1 year
INR56.89
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
INR8.05
Return On Investment
11.2%

For what price can you sell your share?

Current Price per Share
INR71.59
Expected price per share
INR60.00 - INR74.80
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Aarey Drugs & Pharmaceuticals Limited (5 min.)




Live pricePrice per Share (EOD)
INR71.59
Intrinsic Value Per Share
INR-25.35 - INR3.88
Total Value Per Share
INR23.49 - INR52.72

2.2. Growth of Aarey Drugs & Pharmaceuticals Limited (5 min.)




Is Aarey Drugs & Pharmaceuticals Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$16.2m$15.5m$667.7k4.1%

How much money is Aarey Drugs & Pharmaceuticals Limited making?

Current yearPrevious yearGrowGrow %
Making money$470.7k$547.9k-$77.1k-16.4%
Net Profit Margin0.8%1.2%--

How much money comes from the company's main activities?

2.3. Financial Health of Aarey Drugs & Pharmaceuticals Limited (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Aarey Drugs & Pharmaceuticals Limited?

Welcome investor! Aarey Drugs & Pharmaceuticals Limited's management wants to use your money to grow the business. In return you get a share of Aarey Drugs & Pharmaceuticals Limited.

First you should know what it really means to hold a share of Aarey Drugs & Pharmaceuticals Limited. And how you can make/lose money.

Speculation

The Price per Share of Aarey Drugs & Pharmaceuticals Limited is INR71.59. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Aarey Drugs & Pharmaceuticals Limited.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Aarey Drugs & Pharmaceuticals Limited, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is INR48.84. Based on the TTM, the Book Value Change Per Share is INR2.01 per quarter. Based on the YOY, the Book Value Change Per Share is INR5.42 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is INR0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Aarey Drugs & Pharmaceuticals Limited.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 INR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per Share
Usd Eps0.020.0%0.020.0%0.020.0%0.020.0%0.020.0%0.020.0%
Usd Book Value Change Per Share0.020.0%0.020.0%0.060.1%0.030.0%0.040.1%0.040.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.020.0%0.020.0%0.060.1%0.030.0%0.040.1%0.040.1%
Usd Price Per Share0.39-0.39-0.51-0.39-0.33-0.17-
Price to Earnings Ratio23.61-23.61-26.42-22.69-17.21-8.60-
Price-to-Total Gains Ratio16.65-16.65-8.06-14.24-12.67-12.67-
Price to Book Ratio0.69-0.69-0.93-0.73-0.65-0.32-
Price-to-Total Gains Ratio16.65-16.65-8.06-14.24-12.67-12.67-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.837603
Number of shares1193
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.020.04
Usd Total Gains Per Share0.020.04
Gains per Quarter (1193 shares)28.0945.42
Gains per Year (1193 shares)112.38181.69
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101121020182172
202252140363354
303373260545536
404504380727718
505625500908900
60674662010901082
70787774012721264
80899886014531446
901011998016351628
10011241110018171810

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%17.00.00.0100.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%17.00.00.0100.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%2.00.08.020.0%2.00.015.011.8%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%17.00.00.0100.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Aarey Drugs & Pharmaceuticals Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--2.0132.0130%5.417-63%2.921-31%3.254-38%3.635-45%
Book Value Per Share--48.83948.8390%46.827+4%45.692+7%42.404+15%33.412+46%
Current Ratio--2.2022.2020%1.697+30%1.836+20%1.779+24%1.752+26%
Debt To Asset Ratio--0.4190.4190%0.562-26%0.526-20%0.538-22%0.550-24%
Debt To Equity Ratio--0.7210.7210%1.284-44%1.162-38%1.200-40%1.315-45%
Dividend Per Share----0%-0%-0%-0%0.016-100%
Enterprise Value---32972407.000-32972407.0000%-438643805.000+1230%-506327337.333+1436%-414273189.000+1156%-414273189.000+1156%
Eps--1.4191.4190%1.652-14%1.467-3%1.801-21%1.806-21%
Ev To Ebitda Ratio---0.273-0.2730%-3.842+1306%-5.596+1947%-4.484+1541%-4.484+1541%
Ev To Sales Ratio---0.007-0.0070%-0.111+1496%-0.124+1677%-0.100+1333%-0.100+1333%
Free Cash Flow Per Share---1.520-1.5200%-1.311-14%-1.217-20%-1.019-33%-1.231-19%
Free Cash Flow To Equity Per Share--0.2170.2170%0.659-67%0.178+22%0.084+157%0.053+307%
Gross Profit Margin--1.0001.0000%0.964+4%0.888+13%0.916+9%0.911+10%
Intrinsic Value_10Y_max--3.878----------
Intrinsic Value_10Y_min---25.353----------
Intrinsic Value_1Y_max---0.717----------
Intrinsic Value_1Y_min---1.577----------
Intrinsic Value_3Y_max---1.312----------
Intrinsic Value_3Y_min---5.602----------
Intrinsic Value_5Y_max---0.891----------
Intrinsic Value_5Y_min---10.540----------
Market Cap2029884337.000+53%950152593.000950152593.0000%1237665195.000-23%956106996.000-1%808721344.600+17%404360672.300+135%
Net Profit Margin--0.0080.0080%0.012-28%0.010-14%0.012-31%0.014-38%
Operating Margin--0.0210.0210%0.025-13%0.021+3%0.021+1%0.020+7%
Operating Ratio--0.9990.9990%0.993+1%0.996+0%0.992+1%0.990+1%
Pb Ratio1.466+53%0.6860.6860%0.932-26%0.733-6%0.646+6%0.323+112%
Pe Ratio50.446+53%23.61323.6130%26.425-11%22.694+4%17.208+37%8.604+174%
Price Per Share71.590+53%33.51033.5100%43.650-23%33.720-1%28.522+17%14.261+135%
Price To Free Cash Flow Ratio-47.101-114%-22.047-22.0470%-33.305+51%-28.207+28%-20.435-7%-10.218-54%
Price To Total Gains Ratio35.568+53%16.64916.6490%8.058+107%14.242+17%12.670+31%12.670+31%
Quick Ratio--1.6801.6800%1.133+48%1.337+26%1.269+32%1.204+40%
Return On Assets--0.0170.0170%0.015+9%0.015+12%0.020-16%0.026-36%
Return On Equity--0.0290.0290%0.035-18%0.032-10%0.044-34%0.059-51%
Total Gains Per Share--2.0132.0130%5.417-63%2.921-31%3.254-38%3.652-45%
Usd Book Value--16202206.80016202206.8000%15534487.800+4%15158036.400+7%14067268.504+15%11084182.041+46%
Usd Book Value Change Per Share--0.0240.0240%0.063-63%0.034-31%0.038-38%0.043-45%
Usd Book Value Per Share--0.5710.5710%0.548+4%0.535+7%0.496+15%0.391+46%
Usd Dividend Per Share----0%-0%-0%-0%0.000-100%
Usd Enterprise Value---385777.162-385777.1620%-5132132.519+1230%-5924029.847+1436%-4846996.311+1156%-4846996.311+1156%
Usd Eps--0.0170.0170%0.019-14%0.017-3%0.021-21%0.021-21%
Usd Free Cash Flow---504223.200-504223.2000%-434783.700-14%-403681.200-20%-338069.811-33%-408474.432-19%
Usd Free Cash Flow Per Share---0.018-0.0180%-0.015-14%-0.014-20%-0.012-33%-0.014-19%
Usd Free Cash Flow To Equity Per Share--0.0030.0030%0.008-67%0.002+22%0.001+157%0.001+307%
Usd Market Cap23749646.743+53%11116785.33811116785.3380%14480682.782-23%11186451.853-1%9462039.732+17%4731019.866+135%
Usd Price Per Share0.838+53%0.3920.3920%0.511-23%0.395-1%0.334+17%0.167+135%
Usd Profit--470796.300470796.3000%547992.900-14%486668.629-3%597818.258-21%599412.319-21%
Usd Revenue--55451366.10055451366.1000%46227039.300+20%50048664.900+11%49673456.137+12%44088185.037+26%
Usd Total Gains Per Share--0.0240.0240%0.063-63%0.034-31%0.038-38%0.043-45%
 EOD+5 -3MRQTTM+0 -0YOY+18 -203Y+20 -185Y+21 -1710Y+21 -19

3.3 Fundamental Score

Let's check the fundamental score of Aarey Drugs & Pharmaceuticals Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1550.446
Price to Book Ratio (EOD)Between0-11.466
Net Profit Margin (MRQ)Greater than00.008
Operating Margin (MRQ)Greater than00.021
Quick Ratio (MRQ)Greater than11.680
Current Ratio (MRQ)Greater than12.202
Debt to Asset Ratio (MRQ)Less than10.419
Debt to Equity Ratio (MRQ)Less than10.721
Return on Equity (MRQ)Greater than0.150.029
Return on Assets (MRQ)Greater than0.050.017
Total6/10 (60.0%)

3.4 Technical Score

Let's check the technical score of Aarey Drugs & Pharmaceuticals Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5073.528
Ma 20Greater thanMa 5064.268
Ma 50Greater thanMa 10057.936
Ma 100Greater thanMa 20050.735
OpenGreater thanClose71.580
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Aarey Drugs & Pharmaceuticals Limited

Aarey Drugs & Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients, intermediates, and specialty chemicals for various industrial applications in India. The company provides mono methyl and die methyl urea, ortho para nitro anisole, 2 bromomethyl 1, and 3 dioxalane and uracile, as well as active pharma ingredients, such as metformin HCL, mefenamic acid, and doxophylline. It also offers chemicals and solvents, including aromatic chemicals, chemical acids, chlor alkalies, glycols and glycol ethers, fiber intermediates, acetates and esters, and chlorinated solvents, as well as industrial alchols, ketones, amines, oleochemicals, intermediates, olefines, phosphates, fertilizers, monomers, and chemicals. In addition, the company trades in industrial solvents and chemicals.The company's pharmaceutical products are used by pharmaceutical formulation manufacturers and pharmaceutical merchant exporters. Aarey Drugs & Pharmaceuticals Limited was incorporated in 1990 and is headquartered in Mumbai, India.

Fundamental data was last updated by Penke on 2025-06-21 15:38:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is not making a profit/loss.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Aarey Drugs & Pharmaceuticals Limited earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compareΒ Aarey Drugs & Pharmaceuticals Limited to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 0.8%Β means thatΒ ₹0.01 for each ₹1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Aarey Drugs & Pharmaceuticals Limited:

  • The MRQ is 0.8%. The company is not making a profit/loss.
  • The TTM is 0.8%. The company is not making a profit/loss.
Trends
Current periodCompared to+/- 
MRQ0.8%TTM0.8%0.0%
TTM0.8%YOY1.2%-0.3%
TTM0.8%5Y1.2%-0.4%
5Y1.2%10Y1.4%-0.1%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Aarey Drugs & Pharmaceuticals Limited is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Aarey Drugs & Pharmaceuticals Limited to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • 1.7% Return on Assets means thatΒ Aarey Drugs & Pharmaceuticals Limited generatedΒ ₹0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Aarey Drugs & Pharmaceuticals Limited:

  • The MRQ is 1.7%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.7%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.7%TTM1.7%0.0%
TTM1.7%YOY1.5%+0.1%
TTM1.7%5Y2.0%-0.3%
5Y2.0%10Y2.6%-0.6%
4.3.1.3. Return on Equity

Shows how efficient Aarey Drugs & Pharmaceuticals Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Aarey Drugs & Pharmaceuticals Limited to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • 2.9% Return on Equity means Aarey Drugs & Pharmaceuticals Limited generated ₹0.03Β for eachΒ ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Aarey Drugs & Pharmaceuticals Limited:

  • The MRQ is 2.9%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 2.9%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ2.9%TTM2.9%0.0%
TTM2.9%YOY3.5%-0.6%
TTM2.9%5Y4.4%-1.5%
5Y4.4%10Y5.9%-1.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Aarey Drugs & Pharmaceuticals Limited.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Aarey Drugs & Pharmaceuticals Limited is operatingΒ .

  • Measures how much profit Aarey Drugs & Pharmaceuticals Limited makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Aarey Drugs & Pharmaceuticals Limited to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 2.1%Β means the company generated ₹0.02 Β for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Aarey Drugs & Pharmaceuticals Limited:

  • The MRQ is 2.1%. The company is operating less efficient.
  • The TTM is 2.1%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ2.1%TTM2.1%0.0%
TTM2.1%YOY2.5%-0.3%
TTM2.1%5Y2.1%+0.0%
5Y2.1%10Y2.0%+0.1%
4.3.2.2. Operating Ratio

Measures how efficient Aarey Drugs & Pharmaceuticals Limited is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.00 means that the operating costs are ₹1.00 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of Aarey Drugs & Pharmaceuticals Limited:

  • The MRQ is 0.999. The company is less efficient in keeping operating costs low.
  • The TTM is 0.999. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.999TTM0.9990.000
TTM0.999YOY0.993+0.007
TTM0.9995Y0.992+0.008
5Y0.99210Y0.990+0.002
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Aarey Drugs & Pharmaceuticals Limited.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Aarey Drugs & Pharmaceuticals Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 2.20Β means the company has ₹2.20 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of Aarey Drugs & Pharmaceuticals Limited:

  • The MRQ is 2.202. The company is able to pay all its short-term debts. +1
  • The TTM is 2.202. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.202TTM2.2020.000
TTM2.202YOY1.697+0.505
TTM2.2025Y1.779+0.423
5Y1.77910Y1.752+0.026
4.4.3.2. Quick Ratio

Measures if Aarey Drugs & Pharmaceuticals Limited is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Aarey Drugs & Pharmaceuticals Limited to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.68Β means the company can pay off ₹1.68 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Aarey Drugs & Pharmaceuticals Limited:

  • The MRQ is 1.680. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.680. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.680TTM1.6800.000
TTM1.680YOY1.133+0.547
TTM1.6805Y1.269+0.411
5Y1.26910Y1.204+0.065
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Aarey Drugs & Pharmaceuticals Limited.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Aarey Drugs & Pharmaceuticals LimitedΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Aarey Drugs & Pharmaceuticals Limited to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.42Β means that Aarey Drugs & Pharmaceuticals Limited assets areΒ financed with 41.9% credit (debt) and the remaining percentage (100% - 41.9%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Aarey Drugs & Pharmaceuticals Limited:

  • The MRQ is 0.419. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.419. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.419TTM0.4190.000
TTM0.419YOY0.562-0.143
TTM0.4195Y0.538-0.119
5Y0.53810Y0.550-0.012
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Aarey Drugs & Pharmaceuticals Limited is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Aarey Drugs & Pharmaceuticals Limited to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 72.1% means that company has ₹0.72 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Aarey Drugs & Pharmaceuticals Limited:

  • The MRQ is 0.721. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.721. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.721TTM0.7210.000
TTM0.721YOY1.284-0.564
TTM0.7215Y1.200-0.480
5Y1.20010Y1.315-0.115
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every ₹1 in earnings Aarey Drugs & Pharmaceuticals Limited generates.

  • Above 15 is considered overpriced butΒ always compareΒ Aarey Drugs & Pharmaceuticals Limited to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 23.61 means the investor is paying ₹23.61Β for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Aarey Drugs & Pharmaceuticals Limited:

  • The EOD is 50.446. Based on the earnings, the company is expensive. -2
  • The MRQ is 23.613. Based on the earnings, the company is fair priced.
  • The TTM is 23.613. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD50.446MRQ23.613+26.833
MRQ23.613TTM23.6130.000
TTM23.613YOY26.425-2.812
TTM23.6135Y17.208+6.405
5Y17.20810Y8.604+8.604
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Aarey Drugs & Pharmaceuticals Limited:

  • The EOD is -47.101. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -22.047. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -22.047. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-47.101MRQ-22.047-25.054
MRQ-22.047TTM-22.0470.000
TTM-22.047YOY-33.305+11.258
TTM-22.0475Y-20.435-1.612
5Y-20.43510Y-10.218-10.218
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Aarey Drugs & Pharmaceuticals Limited is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 0.69 means the investor is paying ₹0.69Β for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of Aarey Drugs & Pharmaceuticals Limited:

  • The EOD is 1.466. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.686. Based on the equity, the company is cheap. +2
  • The TTM is 0.686. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.466MRQ0.686+0.780
MRQ0.686TTM0.6860.000
TTM0.686YOY0.932-0.246
TTM0.6865Y0.646+0.040
5Y0.64610Y0.323+0.323
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets2,382,662
Total Liabilities997,858
Total Stockholder Equity1,384,805
 As reported
Total Liabilities 997,858
Total Stockholder Equity+ 1,384,805
Total Assets = 2,382,662

Assets

Total Assets2,382,662
Total Current Assets2,132,837
Long-term Assets249,825
Total Current Assets
Cash And Cash Equivalents 14,733
Short-term Investments 17,561
Net Receivables 1,595,472
Inventory 454,803
Other Current Assets 67,829
Total Current Assets  (as reported)2,132,837
Total Current Assets  (calculated)2,150,398
+/- 17,561
Long-term Assets
Property Plant Equipment 162,206
Long-term Assets  (as reported)249,825
Long-term Assets  (calculated)162,206
+/- 87,619

Liabilities & Shareholders' Equity

Total Current Liabilities968,804
Long-term Liabilities29,054
Total Stockholder Equity1,384,805
Total Current Liabilities
Short-term Debt 328,694
Short Long Term Debt 328,694
Accounts payable 541,477
Other Current Liabilities 98,633
Total Current Liabilities  (as reported)968,804
Total Current Liabilities  (calculated)1,297,498
+/- 328,694
Long-term Liabilities
Long term Debt 19,866
Long-term Liabilities Other -1
Long-term Liabilities  (as reported)29,054
Long-term Liabilities  (calculated)19,865
+/- 9,189
Total Stockholder Equity
Common Stock280,543
Accumulated Other Comprehensive Income 24,650
Other Stockholders Equity 1,079,612
Total Stockholder Equity (as reported)1,384,805
Total Stockholder Equity (calculated)1,384,805
+/-0
Other
Capital Stock280,543
Cash and Short Term Investments 14,733
Common Stock Shares Outstanding 27,954
Liabilities and Stockholders Equity 2,382,662
Net Debt 333,827
Net Invested Capital 1,733,365
Net Working Capital 1,164,030
Short Long Term Debt Total 348,560



6.2. Balance Sheets Structured

Currency in INR. All numbers in thousands.

 Trend2025-03-312024-03-312023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312014-03-312013-03-312012-03-312011-03-312010-03-312009-03-312008-03-31
> Total Assets 
0
154,037
261,204
426,637
868,363
1,071,159
1,068,889
1,149,493
1,249,974
1,432,664
1,697,918
1,457,154
1,940,832
2,330,357
2,451,688
2,913,245
3,032,941
2,382,662
2,382,6623,032,9412,913,2452,451,6882,330,3571,940,8321,457,1541,697,9181,432,6641,249,9741,149,4931,068,8891,071,159868,363426,637261,204154,0370
   > Total Current Assets 
0
115,789
208,392
372,377
818,882
993,832
1,016,624
1,085,857
1,167,069
1,306,809
1,572,886
1,329,924
1,813,440
2,183,775
2,263,236
2,706,057
2,825,867
2,132,837
2,132,8372,825,8672,706,0572,263,2362,183,7751,813,4401,329,9241,572,8861,306,8091,167,0691,085,8571,016,624993,832818,882372,377208,392115,7890
       Cash And Cash Equivalents 
0
3,961
1,622
3,792
11,420
5,095
8,488
1,715
16,217
10,379
5,237
3,455
4,873
6,367
1,919
7,058
15,944
14,733
14,73315,9447,0581,9196,3674,8733,4555,23710,37916,2171,7158,4885,09511,4203,7921,6223,9610
       Short-term Investments 
0
0
0
0
0
400
400
400
0
4,338
28,660
233
154
130
75,068
4,180
12,954
17,561
17,56112,9544,18075,06813015423328,6604,338040040040000000
       Net Receivables 
0
0
0
196,338
557,089
664,057
648,505
667,131
724,787
818,566
952,972
1,057,448
961,333
1,620,123
1,362,830
1,997,062
1,844,777
1,595,472
1,595,4721,844,7771,997,0621,362,8301,620,123961,3331,057,448952,972818,566724,787667,131648,505664,057557,089196,338000
       Other Current Assets 
0
81,725
159,400
131,483
124,047
249,497
308,322
375,348
405,300
20,001
49,418
56,285
85,085
87,883
337,324
45,963
232,255
67,829
67,829232,25545,963337,32487,88385,08556,28549,41820,001405,300375,348308,322249,497124,047131,483159,40081,7250
   > Long-term Assets 
0
38,247
52,812
54,260
49,480
77,327
52,266
63,636
82,906
125,855
125,032
127,230
127,393
146,581
188,452
207,187
207,074
249,825
249,825207,074207,187188,452146,581127,393127,230125,032125,85582,90663,63652,26677,32749,48054,26052,81238,2470
       Property Plant Equipment 
0
38,231
52,796
54,032
48,210
44,086
47,150
58,923
78,506
121,455
120,948
123,146
123,393
142,581
144,666
139,368
129,611
162,206
162,206129,611139,368144,666142,581123,393123,146120,948121,45578,50658,92347,15044,08648,21054,03252,79638,2310
       Other Assets 
0
0
0
0
0
0
0
0
0
0
481
481
0
0
0
1
-16,980
0
0-16,98010004814810000000000
> Total Liabilities 
0
70,062
169,124
207,586
540,243
736,456
723,677
795,403
883,001
929,066
895,471
591,628
1,017,371
1,341,752
1,315,316
1,739,107
1,705,207
997,858
997,8581,705,2071,739,1071,315,3161,341,7521,017,371591,628895,471929,066883,001795,403723,677736,456540,243207,586169,12470,0620
   > Total Current Liabilities 
0
55,031
125,383
174,644
540,071
734,763
723,535
795,403
882,126
928,340
881,932
576,324
1,002,778
1,326,120
1,300,762
1,681,349
1,665,469
968,804
968,8041,665,4691,681,3491,300,7621,326,1201,002,778576,324881,932928,340882,126795,403723,535734,763540,071174,644125,38355,0310
       Short-term Debt 
0
0
2,602
26,878
44,137
46,913
46,667
91,410
144,479
61,036
-8,388
161,164
178,684
180,172
108,225
333,575
281,280
328,694
328,694281,280333,575108,225180,172178,684161,164-8,38861,036144,47991,41046,66746,91344,13726,8782,60200
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
31,795
161,164
178,684
180,172
141,625
333,575
281,279
328,694
328,694281,279333,575141,625180,172178,684161,16431,7950000000000
       Accounts payable 
0
0
0
149,014
480,751
677,272
640,807
671,438
719,451
706,187
727,607
372,785
730,448
1,103,399
1,096,615
1,273,315
1,289,430
541,477
541,4771,289,4301,273,3151,096,6151,103,399730,448372,785727,607706,187719,451671,438640,807677,272480,751149,014000
       Other Current Liabilities 
0
55,031
122,781
-1,249
6,591
10,578
15,363
11,127
6,761
40,953
81,562
40,198
75,697
40,018
35,104
56,683
91,813
98,633
98,63391,81356,68335,10440,01875,69740,19881,56240,9536,76111,12715,36310,5786,591-1,249122,78155,0310
   > Long-term Liabilities 
0
15,031
43,741
32,942
172
1,693
142
0
875
725
13,539
15,304
14,593
15,632
14,554
57,758
39,738
29,054
29,05439,73857,75814,55415,63214,59315,30413,53972587501421,69317232,94243,74115,0310
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
12,975
14,918
14,402
33,713
14,554
0
0
0
00014,55433,71314,40214,91812,9750000000000
> Total Stockholder Equity
0
83,975
92,080
219,050
328,120
334,702
345,212
354,091
366,973
503,599
802,447
865,526
923,462
988,605
1,136,373
1,174,138
1,327,734
1,384,805
1,384,8051,327,7341,174,1381,136,373988,605923,462865,526802,447503,599366,973354,091345,212334,702328,120219,05092,08083,9750
   Common Stock
0
50,004
50,004
50,004
140,122
168,147
168,147
168,147
168,147
180,847
233,847
233,847
233,847
233,847
253,847
253,847
280,543
280,543
280,543280,543253,847253,847233,847233,847233,847233,847180,847168,147168,147168,147168,147140,12250,00450,00450,0040
   Retained Earnings Total Equity000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
2,000
2,000
2,000
2,000
12,307
25,150
25,150
25,150
25,150
25,150
25,150
24,650
24,650
24,65024,65025,15025,15025,15025,15025,15025,15012,3072,0002,0002,0002,00000000
   Capital Surplus 000000000000000000
   Treasury Stock000000000000000000
   Other Stockholders Equity 
0
2,000
2,000
121,065
137,178
107,153
107,153
107,153
107,153
165,597
348,522
348,522
348,522
348,522
410,842
410,842
516,110
1,079,612
1,079,612516,110410,842410,842348,522348,522348,522348,522165,597107,153107,153107,153107,153137,178121,0652,0002,0000



6.3. Balance Sheets

Currency in INR. All numbers in thousands.




6.4. Cash Flows

Currency in INR. All numbers in thousands.




6.5. Income Statements

Currency in INR. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2025-03-31. Currency in INR. All numbers in thousands.

Gross Profit (+$)
totalRevenue4,739,433
Cost of Revenue-4,648,116
Gross Profit91,31791,317
 
Operating Income (+$)
Gross Profit91,317
Operating Expense-88,252
Operating Income3,0653,065
 
Operating Expense (+$)
Research Development0
Selling General Administrative33,657
Selling And Marketing Expenses0
Operating Expense88,25233,657
 
Net Interest Income (+$)
Interest Income0
Interest Expense-40,170
Other Finance Cost-0
Net Interest Income-40,170
 
Pretax Income (+$)
Operating Income3,065
Net Interest Income-40,170
Other Non-Operating Income Expenses0
Income Before Tax (EBT)61,019-54,889
EBIT - interestExpense = 61,019
61,019
80,409
Interest Expense40,170
Earnings Before Interest and Taxes (EBIT)101,189101,189
Earnings Before Interest and Taxes (EBITDA)120,638
 
After tax Income (+$)
Income Before Tax61,019
Tax Provision-20,780
Net Income From Continuing Ops40,23940,239
Net Income40,239
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses4,736,368
Total Other Income/Expenses Net57,95440,170
 

Technical Analysis of Aarey Drugs & Pharmaceuticals Limited
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Aarey Drugs & Pharmaceuticals Limited. The general trend of Aarey Drugs & Pharmaceuticals Limited is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Aarey Drugs & Pharmaceuticals Limited's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (85.7%) Bearish trend (-85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Aarey Drugs & Pharmaceuticals Limited Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Aarey Drugs & Pharmaceuticals Limited.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 72.50 < 74.80.

The bearish price targets are: 66.98 > 65.50 > 60.00.

Know someone who trades $AAREYDRUGS? Share this with them.πŸ‘‡

Aarey Drugs & Pharmaceuticals Limited Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Aarey Drugs & Pharmaceuticals Limited. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Aarey Drugs & Pharmaceuticals Limited Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Aarey Drugs & Pharmaceuticals Limited. The current macd is 4.45077369.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Aarey Drugs & Pharmaceuticals Limited price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Aarey Drugs & Pharmaceuticals Limited. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Aarey Drugs & Pharmaceuticals Limited price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Aarey Drugs & Pharmaceuticals Limited Daily Moving Average Convergence/Divergence (MACD) ChartAarey Drugs & Pharmaceuticals Limited Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Aarey Drugs & Pharmaceuticals Limited. The current adx is 33.87.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Aarey Drugs & Pharmaceuticals Limited shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Aarey Drugs & Pharmaceuticals Limited Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Aarey Drugs & Pharmaceuticals Limited. The current sar is 69.42.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Aarey Drugs & Pharmaceuticals Limited Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Aarey Drugs & Pharmaceuticals Limited. The current rsi is 73.53. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
  • Trending up: The RSI is trending up. +1
Aarey Drugs & Pharmaceuticals Limited Daily Relative Strength Index (RSI) ChartAarey Drugs & Pharmaceuticals Limited Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Aarey Drugs & Pharmaceuticals Limited. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Aarey Drugs & Pharmaceuticals Limited price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Aarey Drugs & Pharmaceuticals Limited Daily Stochastic Oscillator ChartAarey Drugs & Pharmaceuticals Limited Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Aarey Drugs & Pharmaceuticals Limited. The current cci is 83.75.

Aarey Drugs & Pharmaceuticals Limited Daily Commodity Channel Index (CCI) ChartAarey Drugs & Pharmaceuticals Limited Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Aarey Drugs & Pharmaceuticals Limited. The current cmo is 48.83.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Aarey Drugs & Pharmaceuticals Limited Daily Chande Momentum Oscillator (CMO) ChartAarey Drugs & Pharmaceuticals Limited Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Aarey Drugs & Pharmaceuticals Limited. The current willr is -5.38261997.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Aarey Drugs & Pharmaceuticals Limited Daily Williams %R ChartAarey Drugs & Pharmaceuticals Limited Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Aarey Drugs & Pharmaceuticals Limited.

Aarey Drugs & Pharmaceuticals Limited Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Aarey Drugs & Pharmaceuticals Limited. The current atr is 2.44162459.

Aarey Drugs & Pharmaceuticals Limited Daily Average True Range (ATR) ChartAarey Drugs & Pharmaceuticals Limited Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Aarey Drugs & Pharmaceuticals Limited. The current obv is 9,072,284.

Aarey Drugs & Pharmaceuticals Limited Daily On-Balance Volume (OBV) ChartAarey Drugs & Pharmaceuticals Limited Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Aarey Drugs & Pharmaceuticals Limited. The current mfi is 98.01.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Aarey Drugs & Pharmaceuticals Limited Daily Money Flow Index (MFI) ChartAarey Drugs & Pharmaceuticals Limited Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Aarey Drugs & Pharmaceuticals Limited.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-20RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-02-21STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-05RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-03-06MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-03-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-19RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-03BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-04-11BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-04-17STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-25RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-04-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-04-29MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-04-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-05-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-05-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-19WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-06-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-25STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-09STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Aarey Drugs & Pharmaceuticals Limited Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Aarey Drugs & Pharmaceuticals Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5073.528
Ma 20Greater thanMa 5064.268
Ma 50Greater thanMa 10057.936
Ma 100Greater thanMa 20050.735
OpenGreater thanClose71.580
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Aarey Drugs & Pharmaceuticals Limited with someone you think should read this too:
  • Are you bullish or bearish on Aarey Drugs & Pharmaceuticals Limited? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Aarey Drugs & Pharmaceuticals Limited? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Aarey Drugs & Pharmaceuticals Limited

I send you an email if I find something interesting about Aarey Drugs & Pharmaceuticals Limited.


Comments

How you think about this?

Leave a comment

Stay informed about Aarey Drugs & Pharmaceuticals Limited.

Receive notifications about Aarey Drugs & Pharmaceuticals Limited in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.